Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	9.2	17.47	51.47	21.66	16.35	11.94
Short-Term Investments	25.32	40.83	40.28	53.17	88.92	128.88
Cash & Short-Term Investments	34.52	58.3	91.75	74.82	105.27	140.82
Cash Growth	-51.35%	-36.45%	22.62%	-28.92%	-25.25%	7.51%
Accounts Receivable	0.19	0.18	0.77	0.29	0.77	0.54
Other Receivables	-	0.3	0.4	0.6	-	-
Receivables	0.19	0.48	1.17	0.89	0.77	0.54
Prepaid Expenses	0.88	1.34	2.14	1.7	5.25	4.77
Total Current Assets	35.59	60.13	95.05	77.41	111.28	146.13
Property, Plant & Equipment	0.81	1.21	2.07	2.95	3.52	3.18
Other Long-Term Assets	0.93	0.55	0.07	1.28	1.39	0.24
Total Assets	37.33	61.88	97.19	81.64	116.19	149.54

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.99	8.09	4.82	1.97	1.96	1.44
Accrued Expenses	6.35	6.83	7.9	7.78	5.18	4.11
Current Portion of Leases	0.46	0.73	0.71	0.69	0.68	0.55
Other Current Liabilities	-	0.74	-	-	-	0.46
Total Current Liabilities	10.8	16.39	13.43	10.44	7.81	6.56
Long-Term Leases	-	0.1	0.81	1.46	2.04	2.57
Total Liabilities	10.8	16.5	14.24	11.9	9.85	9.13

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	478.19	475.36	467.09	409.34	404.83	400.5
Retained Earnings	-451.61	-430.03	-384.18	-339.54	-298.1	-259.81
Comprehensive Income & Other	-0.06	0.05	0.03	-0.07	-0.4	-0.28
Total Common Equity	26.53	45.39	82.95	69.74	106.34	140.42
Shareholders' Equity	26.53	45.39	82.95	69.74	106.34	140.42
Total Liabilities & Equity	37.33	61.88	97.19	81.64	116.19	149.54

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.46	0.83	1.52	2.15	2.72	3.12
Net Cash (Debt)	34.06	57.47	90.22	72.67	102.55	137.7
Net Cash Growth	-51.18%	-36.30%	24.15%	-29.13%	-25.53%	5.83%
Net Cash Per Share	0.50	0.86	1.89	1.63	2.35	3.53
Filing Date Shares Outstanding	77.8	68.36	66.52	44.68	44.68	43.31
Total Common Shares Outstanding	68.5	68.31	66.52	44.68	44.68	41.96
Working Capital	24.8	43.73	81.63	66.97	103.48	139.57
Book Value Per Share	0.39	0.66	1.25	1.56	2.38	3.35
Tangible Book Value	26.53	45.39	82.95	69.74	106.34	140.42
Tangible Book Value Per Share	0.39	0.66	1.25	1.56	2.38	3.35
Machinery	2.18	2.48	2.47	2.42	2.12	1.86
Leasehold Improvements	2.57	2.57	2.57	2.57	2.56	1.96

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 6, 2026

Data Sources Report a data error